RxDoctor Payments DataLook up a doctor →

John Hemphill, MD

Neurology with Special Qualifications in Child Neurology · Savannah, GANPI 1285672329

Payments from drug & device makers

$4,935,972in general payments, 2019–2025

Across 4,079 payments — averaging $1210.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$984K
  • Novartis$897K
  • Sanofi$652K
  • Eisai Inc.$313K
  • Amgen$312K
  • EMD Serono, Inc.$265K
  • plus $1.5M from 54 others
$55,113in research payments, 2019–2025

Across 16 payments — averaging $3444.57 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$46K
  • Sanofi US Services Inc.$7K
  • Acadia Pharmaceuticals Inc$2K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)504$983,713
Novartis107$896,802
Sanofi187$651,551
Eisai Inc.339$312,697
Amgen(2 entities)368$311,722
EMD Serono, Inc.457$265,000
AstraZeneca(2 entities)167$172,532
TG Therapeutics, Inc.87$171,073
Adamas Pharmaceuticals, Inc.41$126,435
Roche Products Limited167$120,376
Bristol Myers Squibb67$106,525
Biogen159$104,744
Argenx US, Inc.109$91,095
Acadia Pharmaceuticals Inc32$83,484
H. Lundbeck A S21$66,194
E.r. Squibb & Sons, L.L.C.37$58,337
Ipsen Innovation46$55,640
Genentech USA, Inc.91$53,886
Eli Lilly6$47,242
Teva Pharmaceuticals USA, Inc.129$42,182
Lundbeck LLC84$36,312
Genentech, Inc.9$28,455
Impel Pharmaceuticals Inc.33$21,032
Jazz Pharmaceuticals Inc.29$20,416
UCB, Inc.103$16,977
Biohaven Pharmaceuticals, Inc.31$15,741
Sanofi-aventis U.S. LLC7$15,071
Merz North America, Inc.14$13,657
Vanda Pharmaceuticals Inc.13$10,173
Biohaven Pharmaceutical Holding Company Ltd.19$7,548
Pfizer46$7,480
SK Life Science, Inc.45$5,516
Mallinckrodt Enterprises LLC10$3,550
Mallinckrodt Hospital Products Inc.37$3,138
Janssen Scientific Affairs, LLC1$1,363
Sunovion Pharmaceuticals Inc.53$665
Sanofi US Services Inc.1$622
Supernus Pharmaceuticals, Inc.118$519
Ipsen Biopharmaceuticals, Inc23$505
Johnson & Johnson(2 entities)16$504
Kyowa Kirin, Inc.20$448
Neurelis, Inc.24$441
Lilly USA, LLC14$426
Neurocrine Biosciences, Inc.19$390
CSL Behring15$356
Axsome Therapeutics, Inc.6$289
Greenwich Biosciences, Inc.14$272
Catalyst Pharmaceuticals, Inc.14$247
Sumitomo Pharma America, Inc.11$204
Scilex Pharmaceuticals Inc.8$161
Merz Pharmaceuticals, LLC8$152
Otsuka America Pharmaceutical, Inc.8$150
Acorda Therapeutics, Inc10$143
Avanir Pharmaceuticals, Inc.8$137
Harmony Biosciences LLC8$136
Octapharma USA, Inc.5$115
Tanabe Pharma America, Inc.7$107
Upsher-smith Laboratories LLC6$100
Revance Therapeutics, Inc.2$98
Averitas Pharma Inc.3$93

How this compares

$4,935,972 in reported general payments places this provider in the 95th percentile of 41 neurology with special qualifications in child neurology providers in Georgia.

See all neurology with special qualifications in child neurology providers in Georgia →

Medicare billing

Part B allowed, 2024
$1,754,629
Medicare patients
695
Services billed
180,251

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other neurology with special qualifications in child neurology in Savannah

See the full list for Georgia →

Where these figures come from

Is this you, or does something look wrong? →